** Shares of drug developer Moleculin Biotech MBRX.O falls 22% at $0.28 in early trading
** Co says it will implement 1-for-25 reverse stock split effective December 1
** A 1-for-25 split means every 25 existing shares will be combined into 1 new share
** Split reduces outstanding shares to about 2.1 million from 51.7 million; authorized shares unchanged at 500 mln - MBRX
** Co's shares will continue to trade on the Nasdaq under the ticker "MBRX," but with a new identification number - MBRX
** Co says shareholders who end up with fractional shares after the split will receive cash instead
** Including session's move, stock down ~83% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Comments